{"id":1994,"date":"2022-06-28T06:17:51","date_gmt":"2022-06-28T06:17:51","guid":{"rendered":"https:\/\/covispharma.com\/?page_id=1994"},"modified":"2023-06-28T09:15:11","modified_gmt":"2023-06-28T09:15:11","slug":"feraheme-isi","status":"publish","type":"page","link":"https:\/\/covispharma.com\/index.php\/products\/feraheme-isi\/","title":{"rendered":"Feraheme ISI"},"content":{"rendered":"<p>[et_pb_section fb_built=&#8221;1&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;#2d81b5&#8243; global_colors_info=&#8221;{}&#8221;][et_pb_row _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;0px||0px||true|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.21.0&#8243; _module_preset=&#8221;default&#8221; header_font=&#8221;Montserrat|600|||||||&#8221; header_text_color=&#8221;#FFFFFF&#8221; header_font_size=&#8221;3rem&#8221; header_line_height=&#8221;3.5rem&#8221; header_font_size_tablet=&#8221;2rem&#8221; header_font_size_phone=&#8221;&#8221; header_font_size_last_edited=&#8221;on|tablet&#8221; header_line_height_tablet=&#8221;2.5rem&#8221; header_line_height_phone=&#8221;&#8221; header_line_height_last_edited=&#8221;on|tablet&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h1>Feraheme<sup>\u00ae<\/sup> ISI (ferumoxytol injection)<\/h1>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221; theme_builder_area=&#8221;post_content&#8221;][et_pb_row _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;0px||||false|false&#8221; global_colors_info=&#8221;{}&#8221; theme_builder_area=&#8221;post_content&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221; theme_builder_area=&#8221;post_content&#8221;][et_pb_text _builder_version=&#8221;4.17.4&#8243; _module_preset=&#8221;default&#8221; text_font=&#8221;||||||||&#8221; text_font_size=&#8221;1.1rem&#8221; text_line_height=&#8221;1.75rem&#8221; link_font=&#8221;Montserrat|500|||||||&#8221; link_text_color=&#8221;#9b9b9b&#8221; link_font_size=&#8221;1rem&#8221; header_2_font=&#8221;|600|||||||&#8221; header_2_font_size=&#8221;1.3rem&#8221; global_colors_info=&#8221;{}&#8221; theme_builder_area=&#8221;post_content&#8221;]<\/p>\n<p style=\"text-align: center;\"><strong>Feraheme Important Safety Information<\/strong><\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=&#8221;4.17.4&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;10px|10px|10px|10px|true|true&#8221; border_width_all=&#8221;4px&#8221; border_color_all=&#8221;#4a4a4a&#8221; global_colors_info=&#8221;{}&#8221; theme_builder_area=&#8221;post_content&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221; theme_builder_area=&#8221;post_content&#8221;][et_pb_text _builder_version=&#8221;4.17.4&#8243; _module_preset=&#8221;default&#8221; text_font=&#8221;||||||||&#8221; text_font_size=&#8221;1.1rem&#8221; text_line_height=&#8221;1.75rem&#8221; link_font=&#8221;Montserrat|500|||||||&#8221; link_text_color=&#8221;#9b9b9b&#8221; link_font_size=&#8221;1rem&#8221; header_2_font=&#8221;|600|||||||&#8221; header_2_font_size=&#8221;1.3rem&#8221; global_colors_info=&#8221;{}&#8221; theme_builder_area=&#8221;post_content&#8221;]<\/p>\n<p style=\"text-align: center;\"><strong>WARNING: RISK FOR SERIOUS HYPERSENSITIVITY\/ANAPHYLAXIS REACTIONS<\/strong><\/p>\n<p><strong>Fatal and serious hypersensitivity reactions including anaphylaxis have occurred in patients receiving Feraheme.\u00a0 Initial symptoms may include hypotension, syncope, unresponsiveness, cardiac\/cardiorespiratory arrest. <\/strong><\/p>\n<ul>\n<li><strong>Only administer Feraheme <\/strong><strong>as an intravenous infusion over at least 15 minutes and only <\/strong><strong>when personnel and therapies are immediately available for the treatment of anaphylaxis and other hypersensitivity reactions<\/strong>.<\/li>\n<li><strong>Observe for signs or symptoms of hypersensitivity reactions during and for at least 30 minutes following Feraheme infusion including monitoring of blood pressure and pulse during and after Feraheme administration<\/strong>.<\/li>\n<li><strong style=\"text-align: center;\">Hypersensitivity reactions have occurred in patients in whom a previous Feraheme dose was tolerated<\/strong><span style=\"text-align: center;\">.<\/span><\/li>\n<\/ul>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=&#8221;4.19.5&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;||||false|false&#8221; global_colors_info=&#8221;{}&#8221; theme_builder_area=&#8221;post_content&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221; theme_builder_area=&#8221;post_content&#8221;][et_pb_text _builder_version=&#8221;4.19.5&#8243; _module_preset=&#8221;default&#8221; text_font=&#8221;||||||||&#8221; text_font_size=&#8221;1.1rem&#8221; text_line_height=&#8221;1.75rem&#8221; link_font=&#8221;Montserrat|500|||||||&#8221; link_text_color=&#8221;#2d81b5&#8243; link_font_size=&#8221;1rem&#8221; header_2_font=&#8221;|600|||||||&#8221; header_2_font_size=&#8221;1.3rem&#8221; global_colors_info=&#8221;{}&#8221; theme_builder_area=&#8221;post_content&#8221;]<\/p>\n<p><span style=\"text-decoration: underline;\"><strong>Indication and Dosages<\/strong><\/span><\/p>\n<p>Feraheme is indicated for the treatment of iron deficiency anemia (IDA) in adult patients who have intolerance oral iron or have had unsatisfactory response to oral iron.<\/p>\n<p>Feraheme is also indicated for the treatment of iron deficiency anemia in adult patients with chronic kidney disease (CKD).<\/p>\n<p>The recommended dose of Feraheme is an initial 510 mg dose followed by a second 510 mg dose as early as 3 days and up to 8 days later, each dose infused over at least 15 minutes while the patient is in a reclined or semi-reclined position.<\/p>\n<p><span style=\"text-decoration: underline;\"><strong>Contraindications<\/strong><\/span><\/p>\n<p>Feraheme is contraindicated in patients with known hypersensitivity to Feraheme or any of its components or a history of allergic reaction to any intravenous iron product.<\/p>\n<p><span style=\"text-decoration: underline;\"><strong>Warnings and Precautions<\/strong><\/span><\/p>\n<p><strong>Hypersensitivity<\/strong>: In addition to the fatal and serious adverse reactions in the Boxed Warning, other adverse reactions associated with hypersensitivity have occurred (pruritus, rash, urticaria, and wheezing). Allergic reactions have occurred following the first dose or subsequent doses in patients in whom a previous dose was tolerated. Patients with a history of multiple drug allergies may have a greater risk of anaphylaxis with parenteral iron products. Carefully consider the potential risks and benefits before administering Feraheme to these patients. Elderly patients with multiple or serious co-morbidities who experience hypersensitivity reactions and\/or hypotension following administration of Feraheme may have more severe outcomes.<\/p>\n<p><strong>Hypotension<\/strong>: Feraheme may cause clinically significant hypotension. <strong>\u00a0<\/strong>Monitor patients for signs and symptoms of hypotension following each Feraheme administration.<\/p>\n<p><strong>Iron Overload:<\/strong> Excessive therapy with parenteral iron can lead to excess storage of iron with the possibility of iatrogenic hemosiderosis. Regularly monitor the hematologic response during parenteral iron therapy. Do not administer Feraheme to patients with iron overload.<\/p>\n<p><strong>Magnetic Resonance (MR) Imaging Test Interference:<\/strong> Administration of Feraheme may transiently affect the diagnostic ability of MR imaging.\u00a0 Alteration of MR imaging studies may persist for up to 3 months following the last Feraheme dose.\u00a0 Maximum alteration of vascular MR imaging is anticipated to be evident for 1 \u2013 2 days following Feraheme administration.<\/p>\n<p><strong><span style=\"text-decoration: underline;\">Adverse Reactions<\/span><br \/><\/strong>The most common adverse reactions (\u2265 2%) are diarrhea, headache, nausea, dizziness, hypotension, constipation, and peripheral edema.<\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=&#8221;4.19.5&#8243; _module_preset=&#8221;default&#8221; text_font=&#8221;||||||||&#8221; text_font_size=&#8221;1.1rem&#8221; text_line_height=&#8221;1.75rem&#8221; link_font=&#8221;Montserrat|500|||||||&#8221; link_text_color=&#8221;#2d81b5&#8243; link_font_size=&#8221;1rem&#8221; header_2_font=&#8221;|600|||||||&#8221; header_2_font_size=&#8221;1.3rem&#8221; hover_enabled=&#8221;0&#8243; global_colors_info=&#8221;{}&#8221; theme_builder_area=&#8221;post_content&#8221; sticky_enabled=&#8221;0&#8243;]<\/p>\n<p><strong>Click <a href=\"https:\/\/dailymed.nlm.nih.gov\/dailymed\/fda\/fdaDrugXsl.cfm?setid=32b0e320-a739-11dc-a704-0002a5d5c51b&amp;type=display\" target=\"_blank\" rel=\"noopener\"><span style=\"text-decoration: underline;\">here<\/span><\/a> to see full Prescribing Information, including Boxed Warning for Feraheme.<\/strong><\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Feraheme\u00ae ISI (ferumoxytol injection)Feraheme Important Safety InformationWARNING: RISK FOR SERIOUS HYPERSENSITIVITY\/ANAPHYLAXIS REACTIONS Fatal and serious hypersensitivity reactions including anaphylaxis have occurred in patients receiving Feraheme.\u00a0 Initial symptoms may include hypotension, syncope, unresponsiveness, cardiac\/cardiorespiratory arrest. Only administer Feraheme as an intravenous infusion over at least 15 minutes and only when personnel and therapies are immediately available [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":1283,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"<!-- wp:divi\/placeholder \/-->","_et_gb_content_width":"","footnotes":""},"class_list":["post-1994","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/covispharma.com\/index.php\/wp-json\/wp\/v2\/pages\/1994"}],"collection":[{"href":"https:\/\/covispharma.com\/index.php\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/covispharma.com\/index.php\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/covispharma.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/covispharma.com\/index.php\/wp-json\/wp\/v2\/comments?post=1994"}],"version-history":[{"count":0,"href":"https:\/\/covispharma.com\/index.php\/wp-json\/wp\/v2\/pages\/1994\/revisions"}],"up":[{"embeddable":true,"href":"https:\/\/covispharma.com\/index.php\/wp-json\/wp\/v2\/pages\/1283"}],"wp:attachment":[{"href":"https:\/\/covispharma.com\/index.php\/wp-json\/wp\/v2\/media?parent=1994"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}